Related Experiment Video

Updated: May 30, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

[Treatment of non-cystic fibrosis bronchiectasis]

Miguel Ángel Martínez García1, Luis Máiz Carro, Pablo Catalán Serra

  • 1Unidad de Neumología, Hospital General de Requena, Valencia, España. m.a.martinez@saludalia.com

Archivos De Bronconeumologia
|July 30, 2011
PubMed

Insights

Bronchiectasis management requires prolonged antibiotic therapy, especially inhaled antibiotics, for bronchial infections. Comprehensive care involves multidisciplinary teams addressing exacerbations, nutrition, and physiotherapy.

Area of Science:

  • Pulmonology
  • Infectious Diseases

Background:

  • Bronchiectasis is increasingly diagnosed, significantly impacting patients' baseline health.
  • Bacterial colonization and infection of the airways are primary drivers of chronic inflammation, leading to bronchial tree destruction and dilation.

Purpose of the Study:

  • To highlight the importance of prolonged antibiotic therapy in managing bronchiectasis-associated infections.
  • To emphasize the growing role of inhaled antibiotics due to their efficacy and safety profile.
  • To underscore the necessity of a multidisciplinary approach for comprehensive patient care.

Main Methods:

  • Review of current treatment strategies for bronchiectasis.
  • Analysis of the role of potentially pathogenic microorganisms (PPM) in disease progression.
  • Evaluation of antibiotic therapy, with a focus on inhaled formulations.

Main Results:

  • Prolonged antibiotic therapy is crucial for controlling chronic bronchial infections in bronchiectasis.
  • Inhaled antibiotics demonstrate high efficacy and a favorable safety profile.
  • Multidisciplinary management is essential for addressing various patient needs.

Conclusions:

  • Effective bronchiectasis management hinges on sustained antibiotic treatment, particularly inhaled options.
  • A holistic, team-based approach is vital for optimizing outcomes, encompassing medical, surgical, and rehabilitative interventions.

More Related Videos

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections06:57

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections

Published on: May 8, 2017

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...